SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal informs about inform press release

05 May 2021 Evaluate

Hikal has informed that it has enclosed a copy of the press release on 5th May 2021, titled ‘Hikal signs a 10-year multi product deal with a leading global pharmaceutical innovator company’ regarding long term contract entered into by the Company with a leading global pharmaceutical innovator company. Treat this as an intimation under Regulation 30 of SEBI LODR.

The above information is a part of company’s filings submitted to BSE.

Hikal Share Price

228.95 -5.30 (-2.26%)
17-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1933.10
Dr. Reddys Labs. 1210.85
Cipla 1418.40
Lupin 2442.10
Zydus Lifesciences 1142.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: